June 2021, Vol 11, No 6

Esophageal cancer is a leading cause of cancer-related morbidity and mortality worldwide. Chemoradiotherapy followed by surgery is the standard of care for patients with resectable, locally advanced esophageal cancer. However, the risk for recurrence after this treatment remains high, especially among the majority of patients who do not have a pathologic complete response. Read Article ›

Previous analyses have pointed to alarming shortages of oncology providers in the face of growing demand. No oncology workforce study, however, has assessed the link between geographic need for oncology services and the codependency between oncologists and nonphysician health professionals with an oncology subspecialty. A recent report on the state of cancer care in the United States examined the availability of physicians and oncology pharmacists and their geographic distributions throughout the country and compared it with the need for oncology services in each county. Read Article ›

The following clinical trials represent a selection of key studies currently recruiting patients with urothelial cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to one of these clinical trials. Read Article ›